-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, The Lancet recently published a large-scale retrospective study based on national surveillance data in Israel, showing that two doses of BNT162b2 (co-developed by Pfizer/BioNTech) vaccine can prevent 95.
3% of new crowns Viral infection.
The data also reveals that widespread vaccine coverage is a key driver of the decline in Israel’s new coronavirus infection rate.
Compared to a number of Israeli data previously published, this study supplements large-scale evidence at the national level.
The corresponding author of the study, Dr.
Sharon Alroy-Preis from the Israeli Ministry of Health, said: "Until now, no studies in the world have described the impact of the nationwide COVID-19 vaccination program on public health.
As the country with the highest rate of COVID-19 vaccination, Israel Research Provides unique real-world data.
" Screenshot source: The Lancet This study is based on national surveillance data from the Israeli Ministry of Health, analyzing the impact of vaccination in the first 4 months on the outcome of new coronavirus infection, incidence, and hospitalization.
Israel started vaccination of the new crown vaccine BNT162b2 on December 20, 2020.
As of April 3, 2021, BNT162b2 is still the only vaccine available locally.
More than 5.
2 million people in Israel have received nearly 10 million doses of the vaccine.
61% of the population has received at least one dose of the new crown vaccine.
Higher than any other country in the world.
Among them, 72% of the nearly 6.
54 million people over the age of 16 have been vaccinated with two doses of the BNT162b2 vaccine.
Among the nearly 1.
13 million people over the age of 65, 90% have completed the vaccination.
All vaccinators received nearly 7 weeks of follow-up after the second dose of vaccination (the average follow-up time was 48 days).
The research team pointed out that this was the "longest follow-up time reported so far.
"
During the follow-up period, a total of 232,268 new coronavirus infections were recorded across Israel, and 7,694 were hospitalized, including 4,481 severe cases, 188 critical cases, and 1113 deaths.
Two-thirds of infections occurred in people over 16 years old, of which 71.
0% were not vaccinated and 4.
1% were fully vaccinated (second dose ≥ 7 days).
The most prevalent virus strain is B.
1.
1.
7 (originally discovered in the UK), which accounts for 94.
5% of Israel's free nucleic acid test samples (8006 cases/8472 cases).
Analysis shows that the BNT162b2 vaccine has a very high protective effect on all people over 16 years old.
7 days after the second dose of vaccination: 95.
3% protection against new coronavirus infections, 91.
5% protection against asymptomatic infections, 97.
0% protection against symptomatic infections (COVID-19), and 97.
0% protection against COVID-19 The protective effect of related hospitalization was 97.
2%, and the protective effect of COVID-19-related hospitalization and the development of severe or critical illness was 97.
5%, and the protective effect of COVID-19-related death was 96.
7%.
14 days after the second dose of the vaccine, the protective efficacy of the vaccine was further improved, preventing 96.
5% of infections, 98.
0% of hospitalizations, and 98.
1% of deaths.
Similar protective effects have also been observed in the elderly.
Even the ultra-old people over 85 years old can prevent 94.
1% of infections, 96.
9% of hospitalizations, and 97% of deaths 7 days after the second dose of vaccine.
In contrast, among people aged 16-44, 7 days after the second dose of the vaccine, 96.
1% of infections, 98.
1% of hospitalizations, and 100% of deaths can be prevented.
▲For people of different age groups, the protective efficacy of two doses of BNT162b2 vaccine 7 days after vaccination (data source: reference [1]; translation and compilation: new medical perspectives) The analysis data also emphasizes the importance of completing the vaccination program.
Compared with two doses, the protective effect within 14-21 days after the first dose of the vaccine is much lower.
It can only prevent 57.
7% of infections, 75.
7% of hospitalizations, and 77.
0% of deaths. The research team emphasized that little is known about the duration of protection of one dose of vaccine and how it compares with two full doses of vaccine.
It is not ruled out that one dose of vaccine may have a shorter protection period, especially in new variants.
Circumstances that keep appearing.
Picture source: 123RF has seen a decrease in infection rates in all age groups across Israel with the increase in vaccination coverage (based on data 7 days after vaccination).
Especially among people over 65 years old, there is a rapid decline-this also reflects the higher vaccination rate and earlier vaccination among the elderly.
For example, before mid-January, the infection rate among people over the age of 65 continued to rise, with the highest single-day infection rate reaching 55 cases per 100,000 people.
However, as people received the second dose of the vaccine, infections began to decrease, and when they gradually began to reopen on February 7, the single-day infection rate was about 30 cases per 100,000 people.
With the widespread coverage of vaccines, the daily infection rate continues to drop significantly.
Among people of all ages, COVID-19 hospitalization, reformation or critical illness, and the decline in mortality are consistent with the increase in vaccine coverage.
The relationship between the infection rate and several lockdown policy adjustments during the study period is not so obvious.
It is worth noting that even after the two reopenings and the final lifting of the lockdown, the decline in the infection rate continued.
This further demonstrates the public health benefits of the vaccination program.
▲In different age groups, as the vaccination rate increases (light blue-first dose; dark blue-second dose), the new coronavirus infection rate (red line) has decreased significantly (picture source: reference [1]) overall In other words, this study confirmed the performance of the previous BNT162b2 vaccine in phase 3 clinical trials through larger data, which is similar to the real protection data in the medical care workers.
These findings provide hope for the new crown vaccine to eventually control the pandemic.
However, the research team also emphasized that there are still many challenges in controlling the new crown pandemic.
At present, whether it is natural infection or vaccination, the duration of immunity is still unknown, and whether the emergence of mutant strains will affect the efficacy of the vaccine still needs to be closely monitored.
In addition, herd immunity also requires continuous increases in vaccination coverage on a global scale.
The research team also admits that the research has limitations, such as differences in the vaccination strategies of countries and the epidemic situation of the new crown.
These conclusions need to be interpreted carefully when they are extended to other regions.
In addition, another important mutant strain, B.
1.
351, originally discovered in South Africa, has also become popular in Israel recently.
However, the B.
1.
351 infection identified by nucleic acid testing during the research period was limited.
Therefore, the BNT162b2 vaccine is effective against this mutant strain.
The impact still needs more evaluation in the future.
In a review article published at the same time in The Lancet, Professor Eyal Leshem from the Chaim Sheba Medical Center in Israel and Professor Annelies Wilder-Smith from the London School of Hygiene & Tropical Medicine stated: “This research suggests that, High vaccine coverage may provide a way out for the pandemic.
” The comment also pointed out, “In view of the current shortage of supplies, the promotion of vaccines must follow the priority recommendations of the World Health Organization to maximize the impact of vaccines on public health.
At the same time .
, We still need to conduct more research on the effectiveness of vaccines, report the effectiveness of vaccines against key mutant strains in a timely manner, understand the protection period of vaccines for different ages, different geographical areas, and the effectiveness of alternative dosing regimens.
This information is important for immunization policies.
Are all crucial. "New crown research related readings on herd immunity may require 80% of the population to complete vaccination! "The Lancet" published the true effect of the new crown vaccine in preventing infection 500,000 vaccination, no serious adverse reactions were found! Sinopharm's new crown inactivated vaccine safety data released Ke Xingmei The detailed data of the Phase 3 trial of live vaccines were announced, 100% prevention of moderate to severe COVID-19 was introduced by Fosun Pharma, and Nature-Medical published the Phase 1 clinical data of the mRNA new crown vaccine.
After the vaccine, how did the Chinese population get infected with the new crown again? NEJM cases explain the impact of virus mutations in detail [1] Eric J Haas, et al.
, (2021).
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
The Lancet, DOI: https://doi.
org/10.
1016/S0140-6736(21)00947-8[2] Eyal Leshem, Annelies Wilder-Smith.
( 2021).
COVID-19 vaccine impact in Israel and a way out of the pandemic.
The Lancet, DOI: https://doi.
org/10.
1016/S0140-6736(21)01018-7[3] The Lancet: First nation -wide data shows two doses of Pfizer-BioNTech vaccine highly effective against COVID-19 infection, hospitalisation, and death.
Retrieved May 6, 2021, from Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation. If you need guidance on treatment plans, please go to a regular hospital for treatment.
3% of new crowns Viral infection.
The data also reveals that widespread vaccine coverage is a key driver of the decline in Israel’s new coronavirus infection rate.
Compared to a number of Israeli data previously published, this study supplements large-scale evidence at the national level.
The corresponding author of the study, Dr.
Sharon Alroy-Preis from the Israeli Ministry of Health, said: "Until now, no studies in the world have described the impact of the nationwide COVID-19 vaccination program on public health.
As the country with the highest rate of COVID-19 vaccination, Israel Research Provides unique real-world data.
" Screenshot source: The Lancet This study is based on national surveillance data from the Israeli Ministry of Health, analyzing the impact of vaccination in the first 4 months on the outcome of new coronavirus infection, incidence, and hospitalization.
Israel started vaccination of the new crown vaccine BNT162b2 on December 20, 2020.
As of April 3, 2021, BNT162b2 is still the only vaccine available locally.
More than 5.
2 million people in Israel have received nearly 10 million doses of the vaccine.
61% of the population has received at least one dose of the new crown vaccine.
Higher than any other country in the world.
Among them, 72% of the nearly 6.
54 million people over the age of 16 have been vaccinated with two doses of the BNT162b2 vaccine.
Among the nearly 1.
13 million people over the age of 65, 90% have completed the vaccination.
All vaccinators received nearly 7 weeks of follow-up after the second dose of vaccination (the average follow-up time was 48 days).
The research team pointed out that this was the "longest follow-up time reported so far.
"
During the follow-up period, a total of 232,268 new coronavirus infections were recorded across Israel, and 7,694 were hospitalized, including 4,481 severe cases, 188 critical cases, and 1113 deaths.
Two-thirds of infections occurred in people over 16 years old, of which 71.
0% were not vaccinated and 4.
1% were fully vaccinated (second dose ≥ 7 days).
The most prevalent virus strain is B.
1.
1.
7 (originally discovered in the UK), which accounts for 94.
5% of Israel's free nucleic acid test samples (8006 cases/8472 cases).
Analysis shows that the BNT162b2 vaccine has a very high protective effect on all people over 16 years old.
7 days after the second dose of vaccination: 95.
3% protection against new coronavirus infections, 91.
5% protection against asymptomatic infections, 97.
0% protection against symptomatic infections (COVID-19), and 97.
0% protection against COVID-19 The protective effect of related hospitalization was 97.
2%, and the protective effect of COVID-19-related hospitalization and the development of severe or critical illness was 97.
5%, and the protective effect of COVID-19-related death was 96.
7%.
14 days after the second dose of the vaccine, the protective efficacy of the vaccine was further improved, preventing 96.
5% of infections, 98.
0% of hospitalizations, and 98.
1% of deaths.
Similar protective effects have also been observed in the elderly.
Even the ultra-old people over 85 years old can prevent 94.
1% of infections, 96.
9% of hospitalizations, and 97% of deaths 7 days after the second dose of vaccine.
In contrast, among people aged 16-44, 7 days after the second dose of the vaccine, 96.
1% of infections, 98.
1% of hospitalizations, and 100% of deaths can be prevented.
▲For people of different age groups, the protective efficacy of two doses of BNT162b2 vaccine 7 days after vaccination (data source: reference [1]; translation and compilation: new medical perspectives) The analysis data also emphasizes the importance of completing the vaccination program.
Compared with two doses, the protective effect within 14-21 days after the first dose of the vaccine is much lower.
It can only prevent 57.
7% of infections, 75.
7% of hospitalizations, and 77.
0% of deaths. The research team emphasized that little is known about the duration of protection of one dose of vaccine and how it compares with two full doses of vaccine.
It is not ruled out that one dose of vaccine may have a shorter protection period, especially in new variants.
Circumstances that keep appearing.
Picture source: 123RF has seen a decrease in infection rates in all age groups across Israel with the increase in vaccination coverage (based on data 7 days after vaccination).
Especially among people over 65 years old, there is a rapid decline-this also reflects the higher vaccination rate and earlier vaccination among the elderly.
For example, before mid-January, the infection rate among people over the age of 65 continued to rise, with the highest single-day infection rate reaching 55 cases per 100,000 people.
However, as people received the second dose of the vaccine, infections began to decrease, and when they gradually began to reopen on February 7, the single-day infection rate was about 30 cases per 100,000 people.
With the widespread coverage of vaccines, the daily infection rate continues to drop significantly.
Among people of all ages, COVID-19 hospitalization, reformation or critical illness, and the decline in mortality are consistent with the increase in vaccine coverage.
The relationship between the infection rate and several lockdown policy adjustments during the study period is not so obvious.
It is worth noting that even after the two reopenings and the final lifting of the lockdown, the decline in the infection rate continued.
This further demonstrates the public health benefits of the vaccination program.
▲In different age groups, as the vaccination rate increases (light blue-first dose; dark blue-second dose), the new coronavirus infection rate (red line) has decreased significantly (picture source: reference [1]) overall In other words, this study confirmed the performance of the previous BNT162b2 vaccine in phase 3 clinical trials through larger data, which is similar to the real protection data in the medical care workers.
These findings provide hope for the new crown vaccine to eventually control the pandemic.
However, the research team also emphasized that there are still many challenges in controlling the new crown pandemic.
At present, whether it is natural infection or vaccination, the duration of immunity is still unknown, and whether the emergence of mutant strains will affect the efficacy of the vaccine still needs to be closely monitored.
In addition, herd immunity also requires continuous increases in vaccination coverage on a global scale.
The research team also admits that the research has limitations, such as differences in the vaccination strategies of countries and the epidemic situation of the new crown.
These conclusions need to be interpreted carefully when they are extended to other regions.
In addition, another important mutant strain, B.
1.
351, originally discovered in South Africa, has also become popular in Israel recently.
However, the B.
1.
351 infection identified by nucleic acid testing during the research period was limited.
Therefore, the BNT162b2 vaccine is effective against this mutant strain.
The impact still needs more evaluation in the future.
In a review article published at the same time in The Lancet, Professor Eyal Leshem from the Chaim Sheba Medical Center in Israel and Professor Annelies Wilder-Smith from the London School of Hygiene & Tropical Medicine stated: “This research suggests that, High vaccine coverage may provide a way out for the pandemic.
” The comment also pointed out, “In view of the current shortage of supplies, the promotion of vaccines must follow the priority recommendations of the World Health Organization to maximize the impact of vaccines on public health.
At the same time .
, We still need to conduct more research on the effectiveness of vaccines, report the effectiveness of vaccines against key mutant strains in a timely manner, understand the protection period of vaccines for different ages, different geographical areas, and the effectiveness of alternative dosing regimens.
This information is important for immunization policies.
Are all crucial. "New crown research related readings on herd immunity may require 80% of the population to complete vaccination! "The Lancet" published the true effect of the new crown vaccine in preventing infection 500,000 vaccination, no serious adverse reactions were found! Sinopharm's new crown inactivated vaccine safety data released Ke Xingmei The detailed data of the Phase 3 trial of live vaccines were announced, 100% prevention of moderate to severe COVID-19 was introduced by Fosun Pharma, and Nature-Medical published the Phase 1 clinical data of the mRNA new crown vaccine.
After the vaccine, how did the Chinese population get infected with the new crown again? NEJM cases explain the impact of virus mutations in detail [1] Eric J Haas, et al.
, (2021).
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
The Lancet, DOI: https://doi.
org/10.
1016/S0140-6736(21)00947-8[2] Eyal Leshem, Annelies Wilder-Smith.
( 2021).
COVID-19 vaccine impact in Israel and a way out of the pandemic.
The Lancet, DOI: https://doi.
org/10.
1016/S0140-6736(21)01018-7[3] The Lancet: First nation -wide data shows two doses of Pfizer-BioNTech vaccine highly effective against COVID-19 infection, hospitalisation, and death.
Retrieved May 6, 2021, from Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation. If you need guidance on treatment plans, please go to a regular hospital for treatment.
